Show simple item record

New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown

dc.contributor.authorDunlap, Denise
dc.contributor.authorSantos, Roberto S.
dc.contributor.authorMcManus, David D.
dc.contributor.authorBuchholz, Bryan O.
dc.contributor.authorHafer, Nathaniel S.
dc.contributor.authorPicard, MaryAnn
dc.date2022-08-11T08:08:10.000
dc.date.accessioned2022-08-23T15:45:15Z
dc.date.available2022-08-23T15:45:15Z
dc.date.issued2020-11-03
dc.date.submitted2021-08-27
dc.identifier.citation<p>Dunlap D, Santos RS, McManus DD, Buchholz BO, Hafer NS, Picard M. New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown. AIB Insights. 2020 Nov 3;20(3):10.46697/001c.17692. doi: 10.46697/001c.17692. PMID: 34413924; PMCID: PMC8372191. <a href="https://doi.org/10.46697/001c.17692">Link to article on publisher's site</a></p>
dc.identifier.issn1938-9590 (Linking)
dc.identifier.doi10.46697/001c.17692
dc.identifier.pmid34413924
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27484
dc.description.abstractThe 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34413924&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectclinical trials
dc.subjectcovid-19
dc.subjectdecentralization
dc.subjectdeglobalization
dc.subjectemerging technologies
dc.subjecthealthcare
dc.subjectUMCCTS funding
dc.subjectClinical Trials
dc.subjectInfectious Disease
dc.subjectInternational Business
dc.subjectInternational Public Health
dc.subjectTechnology and Innovation
dc.subjectVirus Diseases
dc.titleNew Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
dc.typeJournal Article
dc.source.journaltitleAIB insights
dc.source.volume20
dc.source.issue3
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1291&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/286
dc.identifier.contextkey24527828
refterms.dateFOA2022-08-23T15:45:15Z
html.description.abstract<p>The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities.</p>
dc.identifier.submissionpathcovid19/286
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentUMass Center for Clinical and Translational Science
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages10.46697/001c.17692


Files in this item

Thumbnail
Name:
17692_new_opportunities_and_ca ...
Size:
451.6Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information.
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information.